Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1,2

Arrow with type: Step 1 Identify your patients

Arrow with type: Step 2 Discover the Beovu treatment framework to your service

Arrow with type: Step 3 Be part of the Beovu journey

 

Some patients with wet AMD who struggle to reach their treatment goals on an anti-VEGF could benefit from Beovu1–3

 

How do I identify which patients currently on an anti-VEGF therapy could benefit from Beovu?

 

Document icon to signify the recent guidance for non-response to treatment followed by an algorithm on how to evaluate a therapy for effectiveness

Recent RCOphth guidance defines a non-responder to anti-VEGF therapy as a patient whose visual acuity declines due to persistent activity of the neovascular complex despite optimally delivered treatment regimen.4

 

As new treatments emerge, there is a need to evaluate the effectiveness of anti-VEGF therapy based on:

1. Efficacy (improved visual or anatomical outcomes)

2. Decrease in treatment burden

 

Icon of a clock indicating reduced treatment burden

Agents with a reduced treatment burden are particularly helpful for patients with comorbidities affecting compliance, and are also useful to allow timely service delivery of care.4

 

To help inform your choice, let’s introduce you to some patients you are likely to encounter in your practice who could reach their treatment goals with Beovu.

Integrate Beovu into your service by using the Beovu national framework for the treatment of patients with nAMD.6

This guidance is from expert UK ophthalmologists and can be further adapted locally as individual services require, to ensure it is tailored to your specific service.6

Preview image of the Beovu national framework for the treatment of patients with nAMD guidance document, which is available to download.

Download

 

Beovu Posology

Infographic to show Beovu dosing regimen.

Download Beovu posology poster

Be Ready for Beovu®

 

Patient case study library

 

Safety profile

 

 

AMD, age-related macular degeneration; CNV, choroidal neovascularisation; CST, central subfield thickness; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; SRF, subretinal fluid; VA, visual acuity; VEGF, vascular endothelial growth factor.

*Illustration is not an actual study subject.
Partial morphology response defined as reduction from baseline of between 25% to 75%.5
The Beovu recommended dose for injection in pre-filled syringe is 6 mg (0.05 ml solution) given as an intravitreal injection every 4 weeks (monthly) for the first 3 doses.1,2 The doctor can then individually determine the treatment intervals based on the disease activity, which is determined on the basis of visual acuity and/or morphological parameters. It is suggested that an assessment of disease activity be made 16 weeks (4 months) after starting treatment. Treatment every 12 weeks (3 months) should be considered in patients with no disease activity. Treatment every 8 weeks (2 months) should be considered for patients with disease activity. If the visual and morphological parameters indicate that the patient will not benefit from further treatment, treatment with Beovu should be discontinued. The interval between two Beovu doses during maintenance treatment should not be less than 8 weeks.1,2

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu®(brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu®(brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. Dugel PU, et al. Ophthalmology 2020;127:72–84.
  4. Royal College of Ophthalmologists. Commissioning Guidance: Age Related Macular Degeneration Services. June 2021.
  5. Amoaku WM, et al. Eye (Lond) 2015;29:721–731.
  6. Pearce I, et al. EURETINA Virtual Congress; 9–12 September 2021.
Rate this content: 
No votes yet
UK | May 2022 | 207581
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]